X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs CADILA HEALTHCARE - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA CADILA HEALTHCARE SANOFI INDIA/
CADILA HEALTHCARE
 
P/E (TTM) x 39.9 19.5 204.5% View Chart
P/BV x 8.6 4.6 186.2% View Chart
Dividend Yield % 1.0 0.9 118.3%  

Financials

 SANOFI INDIA   CADILA HEALTHCARE
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
CADILA HEALTHCARE
Mar-18
SANOFI INDIA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs4,560558 817.2%   
Low Rs4,400362 1,217.2%   
Sales per share (Unadj.) Rs1,028.5116.3 884.4%  
Earnings per share (Unadj.) Rs129.017.9 721.8%  
Cash flow per share (Unadj.) Rs186.023.1 804.0%  
Dividends per share (Unadj.) Rs68.003.50 1,942.9%  
Dividend yield (eoy) %1.50.8 199.4%  
Book value per share (Unadj.) Rs753.685.4 882.3%  
Shares outstanding (eoy) m23.031,023.74 2.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.44.0 110.2%   
Avg P/E ratio x34.725.7 135.0%  
P/CF ratio (eoy) x24.119.9 121.2%  
Price / Book Value ratio x5.95.4 110.4%  
Dividend payout %52.719.6 269.2%   
Avg Mkt Cap Rs m103,174470,664 21.9%   
No. of employees `0003.611.8 30.7%   
Total wages/salary Rs m3,59218,545 19.4%   
Avg. sales/employee Rs Th6,537.710,072.7 64.9%   
Avg. wages/employee Rs Th991.41,569.1 63.2%   
Avg. net profit/employee Rs Th819.81,547.7 53.0%   
INCOME DATA
Net Sales Rs m23,686119,049 19.9%  
Other income Rs m7081,132 62.5%   
Total revenues Rs m24,394120,181 20.3%   
Gross profit Rs m5,28128,475 18.5%  
Depreciation Rs m1,3135,388 24.4%   
Interest Rs m15911 1.6%   
Profit before tax Rs m4,66123,308 20.0%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6915,644 30.0%   
Profit after tax Rs m2,97018,292 16.2%  
Gross profit margin %22.323.9 93.2%  
Effective tax rate %36.324.2 149.8%   
Net profit margin %12.515.4 81.6%  
BALANCE SHEET DATA
Current assets Rs m15,67382,005 19.1%   
Current liabilities Rs m6,67860,720 11.0%   
Net working cap to sales %38.017.9 212.4%  
Current ratio x2.31.4 173.8%  
Inventory Days Days7673 103.9%  
Debtors Days Days2298 22.7%  
Net fixed assets Rs m8,09883,703 9.7%   
Share capital Rs m2301,024 22.5%   
"Free" reserves Rs m17,08886,421 19.8%   
Net worth Rs m17,35687,445 19.8%   
Long term debt Rs m025,551 0.0%   
Total assets Rs m25,400180,653 14.1%  
Interest coverage x311.726.6 1,172.6%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.90.7 141.5%   
Return on assets %11.810.6 110.6%  
Return on equity %17.120.9 81.8%  
Return on capital %26.922.0 122.5%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,14542,683 16.7%   
Fx outflow Rs m6,84611,242 60.9%   
Net fx Rs m29931,441 1.0%   
CASH FLOW
From Operations Rs m3,2269,193 35.1%  
From Investments Rs m-1,555-9,737 16.0%  
From Financial Activity Rs m-1,818515 -353.0%  
Net Cashflow Rs m-147-29 506.9%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 8.3 173.5%  
FIIs % 14.6 5.9 247.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 11.0 95.5%  
Shareholders   15,184 44,069 34.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   NOVARTIS  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ASTRAZENECA PHARMA  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 21, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - SUVEN LIFE COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS